AAGL

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
AAGL, Patient, TMS, Investment, Endometriosis, Therapy, USD, Marketing, Congress, Urology, Teaching hospital, INPI, Food, Prostate cancer, EAU, Cancer, Hospital, Intellectual property, AUA, FDA, Diagnosis, DIE, Growth, EDAP, Operating cost, EDT, Randomized controlled trial

Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.

Key Points: 
  • Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.
  • The increase was driven by 10 Focal One systems sold in the fourth quarter of 2023 versus 7 systems sold in the fourth quarter of 2022.
  • Total revenue in the Distribution business for the fourth quarter of 2023 was EUR 9.9 million (USD 10.7 million), as compared to EUR 6.7 million (USD 7.0 million) for the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was EUR 3.5 million (USD 3.8 million), compared to an operating loss of EUR 1.6 million (USD 1.6 million) in the fourth quarter of 2022.

EDAP Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
University of Zurich, AAGL, Hospital, EUR, USD, Overalls, Cleveland Clinic, International Symposium on Endovascular Therapy, Operating cost, EDT, Teaching hospital, University of Florida, Icahn School of Medicine at Mount Sinai, EDAP, League of European Research Universities, Prostate cancer, DACH, League, Marketing, Immunotherapy, University, Investment, Patient, TMS, Congress, Conference, Endo, Research, Growth, SEP, European Society of Gynaecological Oncology, Total, Poster, Lithotripsy, Mount Sinai Hospital, Randomized controlled trial, Pharmaceutical industry, Medical imaging, Film industry, Video game, Lithium, Medicine, Distribution, Urology

- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -

Key Points: 
  • - Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -
    - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology -
    - Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT -
    LYON, France, November 9, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023.
  • The decrease was driven by 1 Focal One system sold in the third quarter 2023 versus 3 systems sold in the third quarter of 2022.
  • Operating loss for the third quarter of 2023 was EUR 5.6 million (USD 6.0 million), compared to an operating loss of EUR 2.1 million (USD 2.2 million) in the third quarter of 2022.
  • A conference call and webcast to discuss the third quarter 2023 financial results will be hosted Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary, today, Thursday, November 9th, 2023, at 8:30am EDT.

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

Retrieved on: 
Wednesday, October 25, 2023
FDA, Food and Drug Administration, Research, AAGL, Woman, Infertility, Pharmaceutical industry

The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.

Key Points: 
  • The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.
  • Femasys is creating accessible innovative options for women, as exemplified by its lead product candidate, FemBloc in late-stage clinical development for permanent birth control and its United States Food and Drug Administration (FDA)-cleared product, FemaSeed® for infertility treatment that is also approved in Canada.
  • The Company is also commercializing complementary diagnostic products, FemVue, FemCath and FemCerv, all of which were internally developed through its in-house manufacturing capabilities, with regulatory approvals in the U.S., Canada and other ex-U.S. territories.
  • Femasys will be exhibiting at booth #1036.

Hologic Announces Innovative Collaboration with AAGL and Inovus Medical to Optimize OB-GYN Training for Minimally Invasive Surgeries

Retrieved on: 
Tuesday, October 10, 2023
Surgery, Women, Consumer, Health, Health Technology, Linda, Omni, Uterine fibroid, Partnership, Accreditation Council for Graduate Medical Education, HOLX, Hysteroscopy, American Board of Obstetrics and Gynecology, Accreditation, AAGL, Graduate medical education, AUB, American Board of Commissioners for Foreign Missions, Patient, Entrepreneurship, Hologic, Gynaecology, Obstetrics, Woman, Life, Birth control, Nursing

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced an innovative new partnership with the American Association of Gynecologic Laparoscopists (AAGL) and Inovus Medical.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced an innovative new partnership with the American Association of Gynecologic Laparoscopists (AAGL) and Inovus Medical.
  • Hologic becomes the chief provider of hysteroscopes for AAGL’s Essentials in Minimally Invasive Gynecologic Surgery (EMIGS) hands-on hysteroscopy skills training for OB-GYN residents.
  • AAGL contracts with Inovus Medical, an award-winning designer and manufacturer of surgical training technologies, for the manufacturing and delivery of the hands-on training equipment for EMIGS.
  • “Our collaboration with Hologic and Inovus provides the vital infrastructure needed to bring EMIGS to life,” said Linda Michels, AAGL Executive Director.

CCRM Fertility Broadens North American Footprint By Adding The Advanced IVF Institute to its Network

Retrieved on: 
Wednesday, August 2, 2023
Advocate Lutheran General Hospital, Medicine, Reproductive medicine, University, Honors colleges and programs, Infertility, Parkland Memorial Hospital, Rosalind Franklin University of Medicine and Science, Research, Gynaecology, IVF, Hospital of the University of Pennsylvania, Fertility, Fertility preservation, MD, Patient, Physician, IIV, Fellow, Education minister, Obstetrics, Hospital, Immunology, AAGL, International Society, Birth control, Science, Northwestern University

CHICAGO, Aug. 2, 2023 /PRNewswire/ -- CCRM Fertility, a global pioneer in fertility treatment, research and science, has added The Advanced IVF Institute, to its rapidly expanding fertility treatment and family-building network. Dr. Charles Miller leads two Chicago-area locations and provides cutting-edge fertility treatments, including in vitro fertilization (IVF), fertility preservation and reproductive surgery.

Key Points: 
  • CHICAGO, Aug. 2, 2023 /PRNewswire/ -- CCRM Fertility , a global pioneer in fertility treatment, research and science, has added The Advanced IVF Institute , to its rapidly expanding fertility treatment and family-building network.
  • Dr. Charles Miller leads two Chicago-area locations and provides cutting-edge fertility treatments, including in vitro fertilization (IVF), fertility preservation and reproductive surgery.
  • For more than 35 years, CCRM Fertility has helped transform lives through exceptional fertility care.
  • As an internationally renowned expert in minimally invasive gynecologic surgery and in the treatment of infertility, Dr. Miller founded The Advanced IVF Institute in 2008.

Dr. Gary Frishman of Boston IVF Named A 2023 Top Fertility Doctor in Rhode Island

Retrieved on: 
Monday, June 5, 2023
Surgical Council on Resident Education, ACOG, Society, Life, American College of Obstetricians and Gynecologists, National Association of Professors of Hebrew, Women's health, System, Top, Reproductive endocrinology and infertility, Clinical professor, IVF, IUI, American Society for Reproductive Medicine, Journal, Brown University, Patient, Physician, Fertility, Council, Big Brothers Big Sisters, ASRM, American College, Reproductive medicine, AAGL, Alpert Medical School, Education, Nursing, Mineral oil, Birth control, Obstetrics, MD, Gynaecology

PROVIDENCE, R.I., June 5, 2023 /PRNewswire-PRWeb/ -- Boston IVF, a worldwide leader of fertility treatment and family building, is pleased to announce that reproductive endocrinologist Gary N. Frishman, MD(he/him) has been selected by Rhode Island Monthly as a 2023 Top Fertility Doctor in Rhode Island.

Key Points: 
  • PROVIDENCE, R.I., June 5, 2023 /PRNewswire-PRWeb/ -- Boston IVF , a worldwide leader of fertility treatment and family building, is pleased to announce that reproductive endocrinologist Gary N. Frishman, MD (he/him) has been selected by Rhode Island Monthly as a 2023 Top Fertility Doctor in Rhode Island.
  • Dr. Frishman has been named a Top Fertility Doctor in every Rhode Island Monthly's Top Doctor article since the award's inception in 1992.
  • Alongside his Rhode Island Monthly recognition, Dr. Frishman has earned national and international acknowledgment for his contributions to Women's Health.
  • Additionally, he has served on the boards of Big Sisters of Rhode Island, Day One Rhode Island, City Year Providence, and Rhode Island Blood Center's Advocacy Board.

The Inner Circle Acknowledges, Stephanie E. Gore as a Top Pinnacle Professional for her contributions to the Obstetrics and Gynecology Fields

Retrieved on: 
Friday, May 26, 2023
AAGL, Bachelor of Science in Nursing, University, Obstetrics, American Board of Obstetrics and Gynecology, National Medical Association, Professional, Multimedia, University of Arizona College of Medicine – Tucson, New York Medical College, Inner circle, American Medical Association, Puberty, American Board of Commissioners for Foreign Missions, Public health, Patient, Physician, University of Arizona, Ulster County, New York, Knowledge, Northern Westchester Hospital, American College, Health, Fellow, Family, ABOG, Female, Nursing, Gynaecology

BRONX, N.Y., May 26, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephanie E. Gore is acknowledged as a Top Pinnacle Professional for her contributions to the Obstetrics and Gynecology Fields.

Key Points: 
  • BRONX, N.Y., May 26, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephanie E. Gore is acknowledged as a Top Pinnacle Professional for her contributions to the Obstetrics and Gynecology Fields.
  • Dr. Gore began her educational journey at The University of Arizona where she earned a Bachelor of Science degree.
  • Dr. Gore delivers babies and has a comprehensive gynecologic practice focusing on robotic laparoscopic surgeries and traditional surgical procedures.
  • A testament to her knowledge and skill, Dr. Gore is board-certification in obstetrics and gynecology through the American Board of Obstetrics and Gynecology (ABOG).

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update

Retrieved on: 
Thursday, March 30, 2023
Colposcopy, Supreme, Surgeon, Bleeding, D&O, Marketing, C More Entertainment, Woman, Infertility, Research, Stage 2, Pain, Research and development, Development, Roe v. Wade, PMA, Standard of care, Administration, Supreme court, Gynaecology, CFO, RAC, IDE, FDA, AAGL, Financial management, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, D, Birth control, Cryptocurrency, Management, Pharmaceutical industry, Medical imaging

ATLANTA, March 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Mr. Elefant brings 25 years of financial management experience at both public and private biopharmaceutical companies.
  • Mr. Elefant has a proven record as a senior level global financial expert with financial reporting, fundraising, and mergers and acquisitions expertise.
  • Sales and marketing expenses were $558,852 for the year ended December 31, 2022, compared to $208,735 for the year ended December 31, 2021.
  • Cost of sales increased to $441,938 for the year ended December 31, 2022, compared to $370,384 for the year ended December 31, 2021.

ABOG Approves AAGL’s EMIGS Training and Testing Program as Option to Meet Surgical Skills Program Standard

Retrieved on: 
Monday, January 9, 2023
Accreditation, Accreditation Council, Physician, ACCME, American Board of Commissioners for Foreign Missions, Certification, OB, ABOG, Knowledge, Faculty, Accreditation Council for Continuing Medical Education, Obstetrics, AMA, AAGL, Continuing medical education, FLS, American Board of Obstetrics and Gynecology, Medicine, Gynaecology

Dallas, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The American Board of Obstetrics and Gynecology (ABOG) has approved the American Association of Gynecologic Laparoscopists (AAGL) Essentials in Minimally Invasive Gynecologic Surgery (EMIGS) Training and Testing Program as an alternative option for candidates to meet the Surgical Skills Program standard for ABOG certification, which was initially announced in 2018.

Key Points: 
  • Dallas, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The American Board of Obstetrics and Gynecology (ABOG) has approved the American Association of Gynecologic Laparoscopists (AAGL) Essentials in Minimally Invasive Gynecologic Surgery (EMIGS) Training and Testing Program as an alternative option for candidates to meet the Surgical Skills Program standard for ABOG certification, which was initially announced in 2018.
  • This standard is part of a broader initiative by ABOG to incorporate simulation and standardize the knowledge and training completed by OB GYN residents.
  • It also establishes an additional objective measure for all U.S. obstetricians and gynecologists applying for specialty certification.
  • Based on feedback from program directors, faculty, and candidates, ABOG considered selecting a gynecology-specific program as an alternative to meet this standard.

Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

Retrieved on: 
Monday, December 12, 2022
Tubing (recreation), Reproductive health, Woman, Surgeon, Annual report, AAGL, FDA, Anesthesia, Safety, Insemination, Risk, Research, Cervical cancer, Infertility, Gynaecology, Birth control, Medical imaging

ATLANTA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today reported that it held a promotional launch of its diagnostic product, FemCerv®, the first endocervical tissue sampler designed to improve tissue quality and quantity at the annual meeting of AAGL (formerly known as the meeting of the American Association for Gynecologic Laparoscopists), where the product was very well received by gynecologic physicians and surgeons. The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.

Key Points: 
  • The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.
  • “Gynecologic specialists acknowledged the novelty of FemCerv, an endocervical curette that obtains a virtually pain free comprehensive tissue sample when evaluating for cervical cancer.
  • FemVue works in conjunction with our other approved product, FemCath™, a selective catheter, which is expected to be commercially available later this month.
  • FemCerv is the first FDA-cleared product designed to capture a complete and uncontaminated endocervical tissue sample in a relatively pain-free procedure.